SecSonar.com

TG Therapeutics, Inc. (TGTX)

TG Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

TG Therapeutics, Inc. (TGTX) is a Biotechnology company based in US with a market capitalization of $5.9B. Revenue grew 87.3% year-over-year and free cash flow was negative at -$25M. This page tracks TGTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 352 employees · IPO May 3, 2010

Valuation

Valuation & price

$39.50 · as of May 17, 2026 · -29.2% vs 52w high

14.3

P/E ratio

Latest-FY diluted EPS

9.08

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$55.83$41.11$26.39Jul 25Dec 25Jul 26Jul 7, 25$35.98Jul 9, 25$37.92Jul 11, 25$37.09Jul 15, 25$37.96Jul 17, 25$39.19Jul 21, 25$37.42Jul 23, 25$37.60Jul 25, 25$36.90Jul 29, 25$35.33Jul 31, 25$35.50Aug 4, 25$28.72Aug 6, 25$27.70Aug 11, 25$26.39Aug 13, 25$27.87Aug 15, 25$28.08Aug 19, 25$27.92Aug 21, 25$28.77Aug 25, 25$28.53Aug 27, 25$28.57Aug 29, 25$29.33Sep 3, 25$31.71Sep 5, 25$32.21Sep 9, 25$32.00Sep 11, 25$32.46Sep 16, 25$31.99Sep 18, 25$32.61Sep 22, 25$34.97Sep 24, 25$35.41Sep 26, 25$35.50Sep 30, 25$36.13Oct 2, 25$36.66Oct 6, 25$36.76Oct 8, 25$35.75Oct 10, 25$33.76Oct 14, 25$34.14Oct 16, 25$34.87Oct 21, 25$35.22Oct 23, 25$33.49Oct 27, 25$33.69Oct 29, 25$33.78Oct 31, 25$34.78Nov 4, 25$33.81Nov 6, 25$33.26Nov 10, 25$30.30Nov 12, 25$31.01Nov 14, 25$31.00Nov 18, 25$31.21Nov 20, 25$30.45Nov 25, 25$32.98Nov 28, 25$33.26Dec 2, 25$30.63Dec 4, 25$31.38Dec 8, 25$30.83Dec 10, 25$30.60Dec 12, 25$31.35Dec 16, 25$30.79Dec 18, 25$29.93Dec 22, 25$31.12Dec 24, 25$31.07Dec 29, 25$30.53Jan 2, 26$29.28Jan 6, 26$29.41Jan 8, 26$30.50Jan 12, 26$27.72Jan 14, 26$29.54Jan 16, 26$30.57Jan 21, 26$31.57Jan 23, 26$31.20Jan 27, 26$30.80Jan 29, 26$30.00Feb 2, 26$29.18Feb 4, 26$29.12Feb 9, 26$29.58Feb 11, 26$28.82Feb 13, 26$28.50Feb 18, 26$29.23Feb 20, 26$29.53Feb 24, 26$30.51Feb 26, 26$30.90Mar 2, 26$29.40Mar 4, 26$29.19Mar 6, 26$29.27Mar 10, 26$29.27Mar 12, 26$26.94Mar 17, 26$31.51Mar 19, 26$30.36Mar 23, 26$30.45Mar 25, 26$31.82Mar 27, 26$31.75Mar 31, 26$33.22Apr 2, 26$33.53Apr 7, 26$33.39Apr 9, 26$34.63Apr 13, 26$33.79Apr 15, 26$34.60Apr 17, 26$35.33Apr 22, 26$38.31Apr 24, 26$36.62Apr 28, 26$34.58Apr 30, 26$33.78May 4, 26$35.71May 6, 26$41.97May 8, 26$42.86May 12, 26$42.54May 14, 26$40.79May 18, 26$39.48May 20, 26$39.76May 22, 26$38.87May 28, 26$38.82Jun 1, 26$37.41Jun 3, 26$40.11Jun 5, 26$40.16Jun 9, 26$43.37Jun 11, 26$48.05Jun 15, 26$50.30Jun 17, 26$51.50Jun 22, 26$54.40Jun 24, 26$53.60Jun 26, 26$55.83Jul 2, 26$53.31
$26.3952-week range$55.83
Loading valuation history…

Fundamentals

Key fundamentals

$5.9B

Market cap

87.3%

Revenue growth (YoY)

83.7%

Gross margin

-$25M

Free cash flow (USD)

$118.8M

Net debt

-0.7%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$152.4KFY 2017$152.4KFY 2018$152.0KFY 2019$152.0KFY 2020$152.0KFY 2021$6.7MFY 2022$2.8MFY 2023$233.7MFY 2024$329.0MFY 2025$616.3M
$152.4K$616.3M

Free cash flow by year

2016 → 2025

FY 2016$-61.9MFY 2017$-93.8MFY 2018$-129.0MFY 2019$-132.9MFY 2020$-214.9MFY 2021$-296.0MFY 2022$-176.2MFY 2023$-31.4MFY 2024$-40.6MFY 2025$-25.0M
-$61.9M-$25M

Gross margin by year

2021 → 2025

FY 202188.2%FY 202290.5%FY 202394.0%FY 202488.3%FY 202583.7%
88.2%83.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 12, 2026Filing
  • 8-K eventPhase 1 Trial ResultsJun 3, 2026Filing
  • 8-K eventPhase 3 Trial ResultsMay 27, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing

Questions

Frequently asked questions

What is TG Therapeutics, Inc.'s market cap?

TG Therapeutics, Inc. (TGTX) has a market capitalization of $5.9B.

What is TGTX's P/E ratio?

TGTX trades at a price-to-earnings ratio of 14.3, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is TGTX's price-to-book (P/B) ratio?

TGTX trades at 9.08 times book value per share.

Are insiders buying TGTX stock?

SEC Form 4 filings show no open-market insider buys at TG Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

PTCT

PTC Therapeutics, Inc.

$6.1B

CNTA

Centessa Pharmaceuticals plc

$6.1B

RYTM

Rhythm Pharmaceuticals, Inc.

$6.2B

LQDA

Liquidia Corporation

$5.5B

CGON

CG Oncology, Inc. Common stock

$5.4B

PTGX

Protagonist Therapeutics, Inc.

$6.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.